A Safety, Tolerability, Pharmacokinetic Study of SHR-6934 Injection in Healthy Subjects

Summary

This study was a randomized, double-blind, single-dose and multi-dose, placebo-controlled phase Ⅰ clinical trial. Six dose groups were planned for the SAD part of the study and four dose groups were planned for the MAD part. A total of 88 healthy subjects were included.

Timeline

Start

2025-01-06

Primary completion

2026-05-10

Completion

2026-05-10

Drugs

Indications